Hims & Hers Benefits from Legal Tailwind in the GLP-1 Market
Reading Time: 3 minutes
Hims & Hers jumps 8% – a court ruling against Eli Lilly provides relief and reduces the major legal risks in the GLP-1 business. Signal for the industry: Compounding remains permitted – strengthening the business model of Hims & Hers and giving investors new confidence. The stock of Hims & Hers Health (NASDAQ: HIMS) rose about eight percent yesterday. The price jump is directly attributable to a ruling that has implications for the telemedicine industry: A U.S. court dismissed a patent lawsuit by Eli Lilly against Willow...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
